Definium Therapeutics, Inc. (MNMD)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
MNMD Chart
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. ( MNMD ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Robert Barrow - CEO & Director Daniel Karlin - Chief Medical Officer Brandi Roberts - Chief Financial Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Sarah Medeiros - Cantor Fitzgerald & Co., Research Division Matthew Hershenhorn - Oppenheimer & Co. Inc., Research Division François Brisebois - LifeSci Capital, LLC Ami Fadia - Needham & Company, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.
Definium Therapeutics, Inc. (MNMD) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Definium Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert Barrow CEO | NASDAQ (NGS) Exchange | 60255C109 CUSIP |
| CA Country | 74 Employees | - Last Dividend | 29 Aug 2022 Last Split | - IPO Date |
Overview
Mind Medicine (MindMed) Inc. is a forward-thinking biopharmaceutical company engaged in the development of innovative products aimed at addressing the complex challenges of brain health disorders. Operating from its headquarters in New York, New York, MindMed is committed to advancing the field of mental health through its groundbreaking research and clinical stage product development. The company focuses on creating novel therapeutic options to improve the lives of patients suffering from conditions for which there are currently limited treatment solutions.
Products and Services
MindMed's portfolio of product candidates reflects the company's dedication to innovation in the treatment of brain health disorders. The following are key developments:
- MM-120: Currently in phase 2 clinical trials, MM-120 is a promising therapeutic candidate for the treatment of generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). This development represents MindMed's commitment to addressing widespread and underserved mental health conditions by targeting their core symptoms through novel pharmacological approaches.
- MM-402: MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, is at the forefront of MindMed's research into autism spectrum disorder (ASD). This compound is in phase I clinical trials with the potential to address the core symptoms of ASD. MindMed's innovative approach with MM-402 underscores its dedication to exploring and expanding therapeutic boundaries in the realm of brain health.
